157 related articles for article (PubMed ID: 30055889)
1. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
Thiele NA; Kärkkäinen J; Sloan KB; Rautio J; Huttunen KM
Bioorg Med Chem Lett; 2018 Sep; 28(17):2856-2860. PubMed ID: 30055889
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
Peura L; Malmioja K; Huttunen K; Leppänen J; Hämäläinen M; Forsberg MM; Gynther M; Rautio J; Laine K
Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Prodrug Size and a Carbonyl Linker on l-Type Amino Acid Transporter 1-Targeted Cellular and Brain Uptake.
Venteicher B; Merklin K; Ngo HX; Chien HC; Hutchinson K; Campbell J; Way H; Griffith J; Alvarado C; Chandra S; Hill E; Schlessinger A; Thomas AA
ChemMedChem; 2021 Mar; 16(5):869-880. PubMed ID: 33230949
[TBL] [Abstract][Full Text] [Related]
4. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
[TBL] [Abstract][Full Text] [Related]
5. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Bhunia S; Vangala V; Bhattacharya D; Ravuri HG; Kuncha M; Chakravarty S; Sistla R; Chaudhuri A
Mol Pharm; 2017 Nov; 14(11):3834-3847. PubMed ID: 28958145
[TBL] [Abstract][Full Text] [Related]
6. L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.
Puris E; Gynther M; Huttunen J; Petsalo A; Huttunen KM
J Control Release; 2017 Sep; 261():93-104. PubMed ID: 28662899
[TBL] [Abstract][Full Text] [Related]
7. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
Hoon M; Petzer JP; Viljoen F; Petzer A
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
[TBL] [Abstract][Full Text] [Related]
8. Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma.
Srisongkram T; Bahrami K; Järvinen J; Timonen J; Rautio J; Weerapreeyakul N
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35955600
[TBL] [Abstract][Full Text] [Related]
9. L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs).
Huttunen J; Gynther M; Vellonen KS; Huttunen KM
Int J Pharm; 2019 Nov; 571():118714. PubMed ID: 31610281
[TBL] [Abstract][Full Text] [Related]
10. High- and low-affinity transport of L-leucine and L-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells.
Soares-da-Silva P; Serrão MP
Am J Physiol Renal Physiol; 2004 Aug; 287(2):F252-61. PubMed ID: 15271688
[TBL] [Abstract][Full Text] [Related]
11. Large neutral amino acid transporter enables brain drug delivery via prodrugs.
Gynther M; Laine K; Ropponen J; Leppänen J; Mannila A; Nevalainen T; Savolainen J; Järvinen T; Rautio J
J Med Chem; 2008 Feb; 51(4):932-6. PubMed ID: 18217702
[TBL] [Abstract][Full Text] [Related]
12. Amino acid ester prodrugs conjugated to the α-carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1).
Rautio J; Kärkkäinen J; Huttunen KM; Gynther M
Eur J Pharm Sci; 2015 Jan; 66():36-40. PubMed ID: 25305508
[TBL] [Abstract][Full Text] [Related]
13. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
Ylikangas H; Malmioja K; Peura L; Gynther M; Nwachukwu EO; Leppänen J; Laine K; Rautio J; Lahtela-Kakkonen M; Huttunen KM; Poso A
ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
[TBL] [Abstract][Full Text] [Related]
14. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells.
Pinho MJ; Serrão MP; Gomes P; Hopfer U; Jose PA; Soares-da-Silva P
Kidney Int; 2004 Jul; 66(1):216-26. PubMed ID: 15200428
[TBL] [Abstract][Full Text] [Related]
16. L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors.
Huttunen KM; Huttunen J; Aufderhaar I; Gynther M; Denny WA; Spicer JA
Int J Pharm; 2016 Feb; 498(1-2):205-16. PubMed ID: 26705152
[TBL] [Abstract][Full Text] [Related]
17. L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia.
Huttunen J; Peltokangas S; Gynther M; Natunen T; Hiltunen M; Auriola S; Ruponen M; Vellonen KS; Huttunen KM
Sci Rep; 2019 Sep; 9(1):12860. PubMed ID: 31492955
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
Ylikangas H; Peura L; Malmioja K; Leppänen J; Laine K; Poso A; Lahtela-Kakkonen M; Rautio J
Eur J Pharm Sci; 2013 Feb; 48(3):523-31. PubMed ID: 23228412
[TBL] [Abstract][Full Text] [Related]
19. Brain uptake of ketoprofen-lysine prodrug in rats.
Gynther M; Jalkanen A; Lehtonen M; Forsberg M; Laine K; Ropponen J; Leppänen J; Knuuti J; Rautio J
Int J Pharm; 2010 Oct; 399(1-2):121-8. PubMed ID: 20727958
[TBL] [Abstract][Full Text] [Related]
20. L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.
Montaser AB; Järvinen J; Löffler S; Huttunen J; Auriola S; Lehtonen M; Jalkanen A; Huttunen KM
ACS Chem Neurosci; 2020 Dec; 11(24):4301-4315. PubMed ID: 33228353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
